- Gene therapy
- Rare diseases
- Oncology
- Infectious disease
- Cell and gene therapy
- Genome editing
- Lentiviral vectors
- Bioproduction process development
- Pre-clinical development
- Gene immunotherapy
- Automated cell separation devices CliniMACS Prodigy and AutoMacs (Miltenyi Biotec)
- Automated cell processing device SEPAX2 (Cytiva)
- Automated CFU Counting Instrument STEMvision™ (STEMCELL Technologies)
- Electroporation system ExPERT ATx™, GTx™ (MaxCyte®)
- Flow cytometer Attune (Thermo Fisher)
- Control Rate Freezer (CRF) (Cytiva)
- Droplet Digital PCR™ (ddPCR™) QX200 reader and QX200 droplet generator (Biorad)
- Automated DNA size selection system Pippin Prep™ (Labtech)
- Bioanalyzer & Chip Priming Station (Agilent Technologies)
- DNA extraction instrument Maxwell® (Promega)
- Bioruptor® Pico Sonication System (Diagenode)
- Bioreactor system BioFlo (Eppendorf), Applikon Mini Bio (Getinge), Celltron shakers (Infors)
- Size and concentration measurements of nanoparticles system Videodrop, (Myriade Lab)
- Chromatography systems ÄKTA Pur et ÄKTA Explorer (Cytiva)
- Tangential Flow Filtration (TFF) KrosFlo® system (Repligen)
- Ultracentrifuge (Beckman)
- Endotoxin testing instrument (Endosafe® nexgen-PTS™)
ART-TG, INSERM US35
The Technological Research Accelerator in Genomic Therapy (ART-TG) is an Inserm gene therapy R&D laboratory whose mission is to promote scientific excellence through technological innovation by accelerating the transfer of discoveries to clinical applications. In particular, we have a unique ability to develop lentiviral vectors bioprocesses production at a pre-industrial stage (for use in CAR-T projects or for the transduction of HSCs) with the associated quality controls.
Our capacity has just been extended to genome-editing processes and preclinical studies in humanised mice, to help new cell and gene therapy projects progress towards clinical trial authorisation.
ART-TG is located in Corbeil-Essonnes (91), south of Paris, within the Evry Genopole, part of the Paris-Saclay University campus and part of the Genother biocluster.
Objectives:
As a Biotherapy Bioproduction Integrator (IBB), ART-TG aims to accelerate innovation by providing the cutting-edge environment required for the early-stage development of cell and gene therapy products. ART-TG Integrator provides services to academic teams and start-ups.
Missions:
- To develop bioproduction process and control methods to de-risk CMC
- To support preclinical studies enabling industrial or clinical transfer
- To provide expertise on pharmaceutical requirements for CMC and IMPD/IND-enabling studies
- To contribute to the structuration of the cell and gene therapy field
- To train the next generation of scientists in the field
- ISO 9001 : 2015 for pre-clinical activities, clinical activities and services in gene therapy
- Academics
TREM2MEDS, EIC European consortium, 2024 – 2027, PI A. BIFFI (UniSMART), A. GALY (Inserm) partner.
The consortium’s 3-year plan includes generation of IMPD-enabling data and packages to launch a first-in-human clinical trial of TREM2-HSPC gene therapy in patients with early onset dementia such as Alzheimer’s and Nasu Hakola diseases carrying TREM2 hypofunctional variants. The role of ART-TG is to support the IND-enabling package for a new lentiviral vector.
Gene therapy of sickle cell disease program, 2024 – 2028, co-coordinated by M. CAVAZZANA (AP-HP) and A. GALY (Inserm).
This program, funded by AFM/Telethon, is a partnership between Inserm, AP-HP, Imagine Institute, IMRB, Généthon and RED Grand Paris. Its supports 3 projects addressing therapeutic innovation and patient data information for sickle cell disease. The role of ART-TG is to develop the process to produce a base-edited product and its preclinical testing.
RHU IRIS, 2019 – 2025, PI M. CAVAZZANA (AP-HP), A. GALY (Inserm) partner.
The objective of this RHU is to establish gene therapy as the reference treatment for replacing Human Leukocyte Antigen-partially-matched Hematopoietic Stem Cell Transplantation to treat severe primary immunodeficiencies. The role of ART-TG is to develop lentiviral vector genomics quality control for patient follow-up.
- Industrials
GENOTHER Biocluster, France 2030 Investment.
GENOTHER is a biocluster of excellence serving the needs of gene therapy project leaders to meet their product development challenges. ART-TG is hosting, as a hub, a genomics and gene-editing analytical platform.
ASMA, “Grand Défi Bioproduction”, 2022-2026, consortium led by Aenitis technologies, A. GALY (Inserm) as partner.
ASMA is a technological innovation project funded by BPI, to integrate acoustic technologies (acoustophoresis and sonoporation) combined with fluidics into genetic material transfection and transduction processes to meet biomanufacturing challenges in cell and gene therapy. The consortium includes 4 teams, Aenitis technologies, ART-TG (Inserm), Yposkesi (SK pharmteco), ART-ARNm.
T2EVOLVE, Europe Horizon 2020 IMI, 2020-2025, co-led by Takeda and University of Wurtzburg, Inserm partner (A. GALY for ART-TG).
T2EVOLVE aims at accelerating the development and increase access to immunotherapy with genetically engineered CAR-T and TCR-T cells. The role of ART-TG is to contribute to the standardization of CAR-T cells quality controls.
